|
1
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Benjamin RS: Osteosarcoma: Better
treatment through better trial design. Lancet Oncol. 16:12–13.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xiong Y, Wu S, Du Q, Wang A and Wang Z:
Integrated analysis of gene expression and genomic aberration data
in osteosarcoma (OS). Cancer Gene Ther. 22:524–529. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lulla RR, Costa FF, Bischof JM, Chou PM,
de F, Bonaldo M, Vanin EF and Soares MB: Identification of
differentially expressed micrornas in osteosarcoma. Sarcoma.
2011:7326902011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Romano F, Garancini M and Uggeri F,
Degrate L, Nespoli L, Gianotti L, Nespoli A and Uggeri F: Surgical
treatment of liver metastases of gastric cancer: State of the art.
World J Surg Oncol. 10:1572012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Olaru AV, Ghiaur G, Yamanaka S, Luvsanjav
D, An F, Popescu I, Alexandrescu S, Allen S, Pawlik TM, Torbenson
M, et al: MicroRNA down-regulated in human cholangiocarcinoma
control cell cycle through multiple targets involved in the G1/S
checkpoint. Hepatology. 54:2089–2098. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hong KJ, Wu DC, Cheng KH, Chen LT and Hung
WC: RECK inhibits stemness gene expression and tumorigenicity of
gastric cancer cells by suppressing ADAM-mediated Notch1
activation. J Cell Physiol. 229:191–201. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma YB, Li GX, Hu JX, Liu X and Shi BM:
Correlation of miR-494 expression with tumor progression and
patient survival in pancreatic cancer. Genet Mol Res.
14:18153–18159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tian C, Zheng G, Zhuang H, Li X, Hu D, Zhu
L, Wang T, You MJ and Zhang Y: MicroRNA-494 activation suppresses
bone marrow stromal cell-mediated drug resistance in acute myeloid
leukemia cells. J Cell Physiol. 232:1387–1395. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lim L, Balakrishnan A, Huskey N, Jones KD,
Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, et al:
MicroRNA-494 within an oncogenic microRNA megacluster regulates
G1/S transition in liver tumorigenesis through suppression of
mutated in colorectal cancer. Hepatology. 59:202–215. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao X, Zhou Y, Chen YU and Yu F: miR-494
inhibits ovarian cancer cell proliferation and promotes apoptosis
by targeting FGFR2. OncolLett. 11:4245–4251. 2016.
|
|
13
|
Yuan J, Wang K and Xi M: miR-494 inhibits
epithelial ovarian cancer growth by targeting c-Myc. Med Sci Monit.
22:617–624. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tian C, Zheng G, Zhuang H, Li X, Hu D, Zhu
L, Wang T, You MJ and Zhang Y: MicroRNA-494 activation suppresses
bone marrow stromal cell-mediated drug resistance inacute myeloid
leukemia cells. J Cell Physiol. 232:1387–1395. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rader J, Russell MR, Hart LS, Nakazawa MS,
Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin
SJ, et al: Dual CDK4/CDK6 inhibition induces cell-cycle arrest and
senescence in neuroblastoma. Clin Cancer Res. 19:6173–6182. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M
and Rajewsky N: Combinatorial microRNA target predictions. Nat
Genet. 37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015. View Article : Google Scholar
|
|
19
|
Griffiths-Jones S, Saini HK, van Dongen S
and Enright AJ: miRBase: Tools for microRNA genomics. Nucleic Acids
Res. 36(Database issue): D154–D158. 2008.PubMed/NCBI
|
|
20
|
Liu S and Feng P: miR-203 determines poor
outcome and suppresses tumor growth by targeting tbk1 in
osteosarcoma. Cell Physiol Biochem. 37:1956–1966. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vanas V, Haigl B, Stockhammer V and
Sutterlüty-Fall H: MicroRNA-21 increases proliferation and
cisplatin sensitivity of osteosarcoma-derived cells. PLoS One.
11:e01610232016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yao J, Qin L, Miao S, Wang X and Wu X:
Overexpression of miR-506 suppresses proliferation and promotes
apoptosis of osteosarcoma cells by targeting astrocyte elevated
gene-1. Oncol Lett. 12:1840–1848. 2016.PubMed/NCBI
|
|
23
|
Li Y, Liu J, Liu ZZ and Wei WB:
MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma
by targeting cyclin-dependent kinase, CDK6. Eur Rev Med Pharmacol
Sci. 20:5117–5125. 2016.PubMed/NCBI
|
|
24
|
Roscigno G, Puoti I, Giordano I,
Donnarumma E, Russo V, Affinito A, Adamo A, Quintavalle C, Todaro
M, Vivanco MD and Condorelli G: miR-24 induces chemotherapy
resistance and hypoxic advantage in breast cancer. Oncotarget.
8:19507–19521. 2017.PubMed/NCBI
|
|
25
|
Zhu D, Tu M, Zeng B, Cai L, Zheng W, Su Z
and Yu Z: Up-regulation of miR-497 confers resistance to
temozolomide in human glioma cells by targeting mTOR/Bcl-2. Cancer
Med. 6:452–462. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shyamasundar S, Lim JP and Bay BH: miR-93
inhibits the invasive potential of triple-negative breast cancer
cells in vitro via protein kinase WNK1. Int J Oncol. 49:2629–2636.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang S, Li X and Zhu H: MicroRNA-152
targets phosphatase and tensin homolog to inhibit apoptosis and
promote cell migration of nasopharyngeal carcinoma cells. Med Sci
Monit. 22:4330–4337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qu Y, Pan S, Kang M, Dong R and Zhao J:
MicroRNA-150 functions as a tumor suppressor in osteosarcomaby
targeting IGF2BP1. Tumour Biol. 37:5275–5284. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang X, Li X, Wu F, Gao H, Wang G, Zheng
H, Wang H, Li J and Chen C: Overexpression of miR-92a promotes the
tumor growth of osteosarcoma by suppressing F-box and WD
repeat-containing protein 7. Gene. 606:10–16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shen PF, Chen XQ, Liao YC, Chen N, Zhou Q,
Wei Q, Li X, Wang J and Zeng H: MicroRNA-494-3p targets CXCR4 to
suppress the proliferation, invasion and migration of prostate
cancer. Prostate. 74:756–767. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao XQ, Liang TJ and Fu JW: miR-494
inhibits invasion and proliferation of gastric cancer by targeting
IGF-1R. Eur Rev Med Pharmacol Sci. 20:3818–3824. 2016.PubMed/NCBI
|
|
32
|
Handschick K, Beuerlein K, Jurida L,
Bartkuhn M, Müller H, Soelch J, Weber A, Dittrich-Breiholz O,
Schneider H, Scharfe M, et al: Cyclin-dependent kinase 6 is a
chromatin-bound cofactor for NF-κB-dependent gene expression. Mol
Cell. 53:193–208. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wiedemeyer WR, Dunn IF, Quayle SN, Zhang
J, Chheda MG, Dunn GP, Zhuang L, Rosenbluh J, Chen S, Xiao Y, et
al: Pattern of retinoblastoma pathway inactivation dictates
response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci USA.
107:pp. 11501–11506. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsai JW, Li CF, Kao YC, Wang JW, Fang FM,
Wang YH, Wu WR, Wu LC, Hsing CH, Li SH, et al: Recurrent
amplification at 7q21.2 Targets CDK6 gene in primary
myxofibrosarcomas and identifies CDK6 overexpression as an
independent adverse prognosticator. Ann Surg Oncol. 19:2716–2725.
2012. View Article : Google Scholar : PubMed/NCBI
|
